Efficacy and Safety of Lenvatinib as a Conversion Therapy for HCC

  • STATUS
    Recruiting
  • participants needed
    50
  • sponsor
    Shanghai Zhongshan Hospital
Send
Updated on 19 February 2024
See if I qualify

Summary

Lenvatinib is the standard of care for patients with advanced hepatocellular carcinoma (HCC). The aim of the single-arm, open-label, phase II clinical trial is to assess efficacy and safety of lenvatinib as a preoperative conversion therapy in patients with potentially resectable HCC. Investigator hypothesized that lenvatinib may be an effective conversion treatment for HCC, and preoperative treatment with lenvatinib can improve resectability in patients with potential resectable HCC and improve the long term survival.

Description

For patients with potentially resectable HCC (intermediate or advanced stage), upfront therapy with surgical resection is of high recurrence rate after surgery. The aim of the single-arm, open-label, prospective phase II clinical trial is to evaluate whether preoperative lenvatinib treatment could improve resectability and therefore improve the long term survival.

Participants who are recruited in this study in this study will be treated with lenvatinib and will be evaluated for the feasibility for surgical resection by a multidisciplinary team every 8 weeks. If the participants underwent curative resection, they will receive lenvatinib treatment for 48 weeks after surgery.

Details
Condition Adenocarcinoma, Adenocarcinoma, HEPATIC NEOPLASM, HEPATOCELLULAR CARCINOMA
Age 18-75 years
Treatment Lenvatinib 4 mg Oral
Clinical Study IdentifierNCT04241523
SponsorShanghai Zhongshan Hospital
Last Modified on19 February 2024

Eligibility

 Yes No Not Sure

Inclusion Criteria

Male or female aged 18-75
The participant must have confirmed diagnosis of HCC histologically or clinically
The participant must have at least one untreated intrahepatic lesion that can be evaluated by contrast-enhanced CT or MRI
The BCLC stage B/C patients, more than 3 tumor nodes or have portal vein tumor thrombus (Vp3-Vp4 according to LCSGJ PVTT classification) or extrahepatic metastases limited to one organ and the number of metastases nodules is no more than 3
ECOG PS 0-1 and Child-Pugh A
Surgical resection is not the first choice according to MDT evaluation
Written informed consent

Exclusion Criteria

WBC<4.0 _10^9/L, HB <80 g/L, PLT<75_10^9/L and NEUT<1.510^9/L
Coagulation function: (prothrombin time) international normalized ratio (INR) >1.2
Liver function: serum albumin (ALB)3.5 g/dl, total bilirubin (TBIL)1.5 times the upper limit of normal range, alanine aminotransferase and aspartate aminotransferase (ALT and AST)3 times the upper limit of normal range; renal function index: serum creatinine (CRE)1.5 times the upper limit of normal range; uncontrolled hypertension (150/90mm Hg)
Lymph node metastasis to hilar of lung or liver, or peripheral tissue adhesion
Participated in other clinical trials 30 days before enrollment
With ascites, hepatic encephalopathy, Gilbert syndrome, sclerosing cholangitis
Suspected allergy to study drug
With other organ dysfunction, it is not expected to be tolerated general anesthesia or hepatectomy
Other conditions that the investigators considered not unsuitable for inclusion
Clear my responses
Read more

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name
Edit Delete

Added by • 

 • 

Private

Edit Delete

Reply by • • Private
Edit Delete

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.